Table 1.
Select demographic and clinical characteristics of the pancreatic ductal adenocarcinoma CT radiomic study cohort (N=71).
| AA (n = 23) | H/L (n = 15) | NHW (n = 33) | Overall | P-value | |
|---|---|---|---|---|---|
| Gender, N (%) | 0.993 | ||||
| Female | 12 (52.2%) | 8 (53.3%) | 17 (51.5%) | 37 (52.1%) | |
| Male | 11 (47.8%) | 7 (46.7%) | 16 (48.5%) | 34 (47.9%) | |
| Age at diagnosis, mean (SD) | 64.9 (10.2) | 61.8 (12.7) | 64.9 (10.1) | 64.2 (10.6) | 0.611 |
| Vital status, N (%) | 0.560 | ||||
| Alive | 4 (17.4%) | 5 (33.3%) | 9 (27.3%) | 18 (25.4%) | |
| Dead | 19 (82.6%) | 10 (66.7%) | 24 (72.7%) | 53 (74.6%) | |
| Smoking status, N (%) | 0.971 | ||||
| Ever | 11 (47.8%) | 9 (60.0%) | 17 (51.5%) | 37 (52.1%) | |
| Missing | 1 (4.35%) | 0 (0.00%) | 1 (3.03%) | 2 (2.82%) | |
| Never | 11 (47.8%) | 6 (40.0%) | 15 (45.5%) | 32 (45.1%) | |
| Marital status, N (%) | 0.516 | ||||
| Divorced | 1 (4.35%) | 3 (20.0%) | 1 (3.03%) | 5 (7.04%) | |
| Married | 17 (73.9%) | 10 (66.7%) | 24 (72.7%) | 51 (71.8%) | |
| Separated | 2 (8.70%) | 1 (6.67%) | 1 (3.03%) | 4 (5.63%) | |
| Single | 1 (4.35%) | 0 (0.00%) | 2 (6.06%) | 3 (4.23%) | |
| Unknown | 0 (0.00%) | 1 (6.67%) | 1 (3.03%) | 2 (2.82%) | |
| Widowed | 2 (8.70%) | 0 (0.00%) | 4 (12.1%) | 6 (8.45%) | |
| Primary site, N (%) | 0.265 | ||||
| C241 Ampulla of vater | 0 (0.00%) | 0 (0.00%) | 2 (6.06%) | 2 (2.82%) | |
| C250 Pancreas Head | 16 (69.6%) | 12 (80.0%) | 25 (75.8%) | 53 (74.6%) | |
| C251 Pancreas Body | 3 (13.0%) | 1 (6.67%) | 1 (3.03%) | 5 (7.04%) | |
| C252 Pancreas Tail | 0 (0.00%) | 2 (13.3%) | 4 (12.1%) | 6 (8.45%) | |
| C257 Pancreas Other Specified | 1 (4.35%) | 0 (0.00%) | 0 (0.00%) | 1 (1.41%) | |
| C258 Pancreas Overlapping | 1 (4.35%) | 0 (0.00%) | 1 (3.03%) | 2 (2.82%) | |
| C259 Pancreas, Not otherwise specified | 2 (8.70%) | 0 (0.00%) | 0 (0.00%) | 2 (2.82%) | |
| SEER Derived Stage, N (%) | 0.257 | ||||
| Localized | 2 (9.09%) | 2 (18.2%) | 6 (18.2%) | 10 (15.2%) | |
| Regional, by direct extension only | 4 (18.2%) | 1 (9.09%) | 5 (15.2%) | 10 (15.2%) | |
| Regional, to lymph nodes only | 4 (18.2%) | 0 (0.00%) | 0 (0.00%) | 4 (6.06%) | |
| Regional, direct extension and lymph nodes | 10 (45.5%) | 6 (54.5%) | 20 (60.6%) | 36 (54.5%) | |
| Distant | 2 (9.09%) | 2 (18.2%) | 2 (6.06%) | 6 (9.09%) | |
| Tumor grade, N (%) | 0.091 | ||||
| Well differentiated | 1 (4.6%) | 0 (0.0%) | 2 (6.01%) | 3 (4.35%) | |
| Moderately differentiated | 8 (36.4%) | 11 (78.6%) | 20 (60.6%) | 39 (56.5%) | |
| Poorly differentiated | 6 (27.3%) | 3 (21.4%) | 8 (24.2%) | 17 (24.6%) | |
| Not determined or Not available | 7 (31.8%) | 0 (0.0%) | 3 (9.1%) | 10 (14.5%) | |
| Clinical tumor size (cm), median (1st ~ 3rd quantile) | 3.20 [2.65;4.68] | 2.90 [2.40;9.05] | 3.65 [2.42;16.0] | 3.20 [2.50;9.60] | 0.796 |
| Pathological tumor size (cm), median (1st ~ 3rd quantile) | 3.0 [2.3;4.7] | 3.2 [3.0;4.9] | 3.0 [2.5;4.9] | 3.0 [2.5;5.2] | 0.602 |
| Regional nodes examined, median (1st ~ 3rd quantile) | 16.0 [0.0;27.2] | 26.0 [21.0;36.5] | 17.0 [13.0;22.0] | 18.5 [13.0;28.0] | 0.005 |
| Regional nodes positive, median (1st ~ 3rd quantile) | 1.0 [0.5;2.5] | 1.0 [0.0;5.5] | 1.0 [0.0;2.0] | 1.0 [0.0;3.0] | 0.840 |
| Survival time (months) median (1st ~ 3rd quantile) | 15.0 [9.0;22.5] | 24.0 [16.0;27.0] | 31.0 [15.0;43.0] | 22.0 [13.0;36.0] | 0.028 |
AA, African Americans; H/L, Hispanic/Latinx; NHW, Non-Hispanic White; CT, computed tomography; SD, standard deviation; SEER, surveillance, epidemiology, end results program
Some numbers and percentages may not add up to the total due to missing data.
Statistically significant differences are noted in bold font.